Rebetol Oral Solution

Pharmacy Times
Volume 0

Schering-Plough Corp (Kenilworth, NJ) has announced the launch of Rebetol (ribavirin USP) Oral Solution for use in combination with Intron A (interferon alfa- 2b, recombinant) Injection for treating pediatric chronic hepatitis C. The combination of Intron A and Rebetol is indicated for the treatment of patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon. Rebetol Oral Solution represents a new formulation of ribavirin USP, developed specifically to meet the needs of pediatric patients. It comes in bubble-gum flavor. For more information, visit www.scheringplough. com.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.